Company intelligence / Profile preview

Anhui Zhifei Longcom Biopharmaceutical

Hefei, Anhui, Chinaen.zhifeishengwu.com ↗

Ownership: Private
Employees: ~4500
Development stage: Other

Overview

Thirteen products launched as of mid–2024 including recombinant COVID‑19 vaccine (CHO cell), pneumococcal vaccines, meningococcal vaccines, influenza vaccines; pipeline includes next-generation norovirus and TB vaccines with positive early clinical data for safety/immunogenicity in multiple age groups.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant proteinGenetically engineered subunit vaccine
Industry: Pharma

Drug pipeline

24 assets

influenza virus split vaccine (low protein, low ovalbumin)

Approved

23 more assets in the full pipeline.

Request access →

Partnerships

Distribution partnerships with Merck Sharp & Dohme for HPV/Rota/Pneumovax/Hepatitis A vaccines

Beyond the preview

Go deeper on Anhui Zhifei Longcom Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anhui Zhifei Longcom Biopharmaceutical.

Explore the full profile